How to achieve a drug formulary that reduces costs and maintains access to care
Since the start of the year and at the apex of the pandemic, nearly 600 drugs have seen price hikes, and more increases from major drug makers are expected soon. Given the continued cost increases, and with many employers looking to ensure affordable access to prescriptions for their members, it’s more important than ever for plan sponsors and benefits professionals to evaluate their formulary to ensure that it provides clinically sound, cost-effective alternatives that can reduce overall plan costs.
Read more by clicking the link to the full article below.
More About BRENT EBERLE
As Senior Vice President, Chief Pharmacy Officer, Brent oversees Navitus’ health strategies division, which is responsible for clinical and population health initiatives, drug utilization review programs, formulary and rebate management, and specialty pharmacy operations.
Stay Informed and Connected
Receive expert insights, healthcare tips, and important updates on pharmacy benefits, drug recalls, and more—straight to your inbox.
Navigating with a trusted partner
Now Available: 9th Annual Drug Trend Report
Our Drug Trend Report provides a clear view of the trends shaping pharmacy benefits today, along with strategies that are delivering real savings without compromising care.
Related blogs
Navigating Healthcare and Improving Outcomes
Legal Ease: Key Legislative & Regulatory Updates Impacting Plan Sponsors in 2025
In this overview of our national Legal Ease webinar event, we highlight key federal and state developments shaping the conversation around PBM reform – and what they mean for your clients. …
Navigating the Drug Supply Chain: What You Need to Know
Before a prescription ever reaches a pharmacy counter, it has already moved through a complex ecosystem known as the drug supply chain. From manufacturers and wholesalers to pharmacy benefit managers (PBMs) and pharmacies, each entity plays a role in…
Real-world Data Demonstrates Successful Transitions from Humira to Biosimilars
Authors: Justin Arzt, PharmD; Agata Siwak, PharmD, MSBA; Marnie Wickizer, PharmD, AE-C, CDCES; Ryan Schmidt, PharmD; Robert Topp, RN, PhD; Matt Hustad, PharmD All authors are employees of Navitus Health Solutions. Abstract Adalimumab biosimilar adoption…
PBM 101: Why the Model Matters
In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are conduits of expertise, analytics and savings opportunities, poised to deliver exceptional health care while driving down costs. They coordinate between drug manufacturers,…
Associate Resource Group Spotlight: Green Team
The Green Team believes that small changes lead to significant impact. Whether its reducing waste, conserving energy or implementing eco-friendly initiatives, they serve as an internal hub for expertise regarding environmental sustainability….
PBM 101: The Three PBM Business Models
In the pharmaceutical and healthcare industry, pharmacy benefit managers (PBMs) are regarded by the media as intermediaries between drug manufacturers, pharmacies, health plans and plan sponsors. But they’re so much more than that. PBMs act as conduits…
An Automated Approach to Diagnosis Verification of GLP-1 RA for Type 2 Diabetes Mellitus (T2DM)
This study examines the impact of implementing an automated point-of-sale diagnosis verification system for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared to traditional utilization management approaches….
Navitus to Remove Stelara® from Formulary July 1, 2025, Adds Biosimilars to Drive $120 Million in Savings
As the nation’s first 100% transparent, pass-through PBM, we continue to advance medication affordability by prioritizing upfront, real-time savings over rebated models….
Pass-Through PBM Partnership Value
Prior to implementing the Navitus Key solution (formerly EpiphanyRx), a mid-size employer in the food industry was grappling with substantial year-over-year increases in per member per month (PMPM) pharmacy costs. The organization struggles to understand…
